nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

21.12.2017 | Assisted Reproduction Technologies

Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes

verfasst von: Jiali Cai, Lanlan Liu, Juan Zheng, Ling Zhang, Xiaoming Jiang, Ping Li, Aiguo Sha, Jianzhi Ren

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to investigate whether individual response of anti-Mullerian hormone (AMH) to gonadotropin-releasing hormone (GnRH) treatment is associated with difference in ovarian stimulation outcomes.

Methods

The retrospective study included 1058 non-polycystic ovary syndrome (PCOS) women undergoing long agonist protocol in a single in vitro fertilization unit from January 1, 2016, through December 31, 2016. Patients were grouped according to AMH changes from day 3 to the day of stimulation (group 1, change < 1 ng/ml, n = 714; group 2, decrease ≥ 1 ng/ml, n = 143; group 3, increase ≥ 1 ng/ml, n = 201). A generalized linear model including Poisson distribution and log link function was used to evaluate the association between AMH response and the number of oocytes retrieved.

Results

Group 2 was characterized by higher basal AMH level and increased AMH to AFC ratio in comparison with two other groups. However, the number of oocytes and ovarian sensitivity index in group 2 was significantly lower than group 3. Adjusted for age, BMI, ovarian reserve markers, and stimulation parameters, the population marginal means (95% confidence interval) of oocyte number in groups 1 through 3 were 9.51 (9.17, 9.86), 8.04 (7.54, 8.58), and 10.65 (10.15, 11.18), respectively. For patients from group 2 and group 3, basal AMH is no longer significantly associated with oocyte yield.

Conclusions

AMH change in response to GnRH agonist varies among individuals; for those undergoing significant changes in AMH following GnRH agonist treatment, basal AMH may not be a reliable marker for ovarian response in long agonist protocol.

Nur mit Berechtigung zugänglich

Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698–710. https://doi.org/10.1093/humupd/dmu062.CrossRefPubMed

La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1):124–40. https://doi.org/10.1093/humupd/dmt037.CrossRefPubMed

Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701. https://doi.org/10.1093/humupd/dmu020.CrossRefPubMed

Jayaprakasan K, Campbell BK, Hopkisson JF, Clewes JS, Johnson IR, Raine-Fenning NJ. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum Reprod. 2008;23(11):2577–83. https://doi.org/10.1093/humrep/den282.CrossRefPubMed

Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women. J Clin Endocr Metab. 2013;98(12):E1961–E6. https://doi.org/10.1210/jc.2013-2410.CrossRefPubMedPubMedCentral

Fauser BCJM, Chang J, Azziz R, Legro R, Dewailly D, Franks S, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098.CrossRef

Ren JZ, Sha AG, Han DM, Li P, Geng J, Ma CH. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment? Fertil Steril. 2014;102(1):75–81. https://doi.org/10.1016/j.fertnstert.2014.03.030.CrossRefPubMed

Martin-Johnston M, Beltsos AN, Grotjan HE, Uhler ML. Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit? Reprod Biomed Online. 2007;15(2):161-168

Madani T, Yeganeh LM, Ezabadi Z,Hasani F, Chehrazi M. Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial. J Assist Reprod Gen. 2012;30(2):239-245

10.

D'Arpe S, Di Feliciantonio M, Candelieri M, Franceschetti S, Piccioni MG, Bastianelli C. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. Reprod BioMed Online. 2016;33(4):436–48. https://doi.org/10.1016/j.rbmo.2016.07.010.CrossRefPubMed

11.

Huang JL, Wang XY, Li ZL, Ma RW, Xiao WF. Effects of GnRH agonists on the expression of developmental follicular anti-Mullerian hormone in varying follicular stages in cyclic mice in vivo. Mol Med Rep. 2015;12(3):4305–13. https://doi.org/10.3892/mmr.2015.3993.CrossRefPubMedPubMedCentral

12.

Singh P, Krishna A. Effects of GnRH agonist treatment on steroidogenesis and folliculogenesis in the ovary of cyclic mice. J Ovarian Res. 2010;3:26. https://doi.org/10.1186/1757–2215–3-26.CrossRefPubMedPubMedCentral

13.

Hagen CP, Sorensen K, Anderson RA, Juul A. Serum levels of antimullerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril. 2012;98(5):1326–30. https://doi.org/10.1016/j.fertnstert.2012.07.1118.CrossRefPubMed

14.

Bhide P, Dilgil M, Gudi A, Shah A, Akwaa C, Homburg R. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril. 2015;103(2):537–41. https://doi.org/10.1016/j.fertnstert.2014.10.033.CrossRefPubMed

15.

Alebic MS, Stojanovic N, Duhamel A, Dewailly D. The phenotypic diversity in per-follicle anti-Mullerian hormone production in polycystic ovary syndrome. Hum Reprod. 2015;30(8):1927–33. https://doi.org/10.1093/humrep/dev131.CrossRefPubMed

16.

Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24(11):2917–23. https://doi.org/10.1093/humrep/dep225.CrossRefPubMed

17.

Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22(6):709–24. https://doi.org/10.1093/humupd/dmw027.CrossRefPubMed

18.

Pierre A, Peigne M, Grynberg M, Arouche N, Taieb J, Hesters L, et al. Loss of LH-induced down-regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod. 2013;28(3):762–9. https://doi.org/10.1093/humrep/des460.CrossRefPubMed

19.

Cimino I, Casoni F, Liu XH, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Mullerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055. https://doi.org/10.1038/ncomms10055.CrossRefPubMedPubMedCentral

20.

Cui LL, Qin YY, Gao X, Lu J, Geng L, Ding LL, et al. Antimullerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil Steril. 2016;105(2):481. https://doi.org/10.1016/j.fertnstert.2015.10.017.CrossRefPubMed

21.

Ashrafi M, Hemat M, Arabipoor A, Salman Yazdi R, Bahman-Abadi A, Cheraghi R. Predictive values of anti-Mullerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2017;37(1):82–8. https://doi.org/10.1080/01443615.2016.1225025.CrossRef

22.

Kunicki M, Lukaszuk K, Jakiel G, Liss J. Serum dehydroepiandrosterone sulphate concentration is not a predictive factor in IVF outcomes before the first cycle of GnRH agonist administration in women with normal ovarian reserve. PLoS One. 2015;10(3):e0118570. https://doi.org/10.1371/journal.pone.0118570.CrossRefPubMedPubMedCentral

23.

Knez J, Kovacic B, Medved M, Vlaisavljevic V. What is the value of anti-Mullerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols? Reproductive Biology and Endocrinology: RB&E. 2015;13:58. https://doi.org/10.1186/s12958-015-0049-5.CrossRef

24.

Heidar Z, Bakhtiyari M, Mirzamoradi M, Zadehmodarres S, Sarfjoo FS, Mansournia MA. Prediction of different ovarian responses using anti-Mullerian hormone following a long agonist treatment protocol for IVF. J Endocrinol Investig. 2015;38(9):1007–15. https://doi.org/10.1007/s40618-015-0297-4.CrossRef

25.

Aydin T, Kara M, Aran T, Turktekin N, Ozdemir B. The association between anti-Mullerian hormone and IVF-ICSI outcome in poor responder patients performing long protocol. Clinical and Experimental Obstetrics & Gynecology. 2015;42(5):663–5.

26.

Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod. 2012;27(6):1829–39. https://doi.org/10.1093/humrep/des101.CrossRefPubMedPubMedCentral

27.

McLennan IS, Pankhurst MW. Is the understanding of AMH being confounded by study designs that do not adequately reflect that it is an atypical hormone? Hum Reprod. 2017;32(1):14–7. https://doi.org/10.1093/humrep/dew305.PubMed

Titel: Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes
verfasst von: Jiali Cai
Lanlan Liu
Juan Zheng
Ling Zhang
Xiaoming Jiang
Ping Li
Aiguo Sha
Jianzhi Ren
Publikationsdatum: 21.12.2017
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 3/2018
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-017-1095-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Increased live births after day 5 versus day 6 transfers of vitrified-warmed blastocysts

HCG administration after endogenous LH rise negatively influences pregnancy rate in modified natural cycle for frozen–thawed euploid blastocyst transfer: a pilot study

Revisiting embryo assisted hatching approaches: a systematic review of the current protocols

One thousand seventy-eight autologous IVF cycles in women 45 years and older: the largest single-center cohort to date

Difference in the size of the placenta and umbilical cord between women with natural pregnancy and those with IVF pregnancy

Cumulative pregnancy and live birth rates through assisted reproduction in women 44–45 years of age: is there any hope?

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie